Tag Archives: Andy Hsieh

William Blair Believes Seattle Genetics (NASDAQ: SGEN) Still Has Room to Grow

William Blair analyst Andy Hsieh reiterated a Buy rating on Seattle Genetics (SGEN – Research Report) on September 18. The company’s shares closed last Friday at $200.93, close to its 52-week high of $213.94. According to TipRanks.com, Hsieh is a

Analysts’ Opinions Are Mixed on These Healthcare Stocks: ImmunoGen (NASDAQ: IMGN), Incyte (NASDAQ: INCY) and Axsome Therapeutics (NASDAQ: AXSM)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ImmunoGen (IMGN – Research Report), Incyte (INCY – Research Report) and Axsome Therapeutics (AXSM – Research Report). ImmunoGen (IMGN) In a report released

William Blair Sticks to Their Buy Rating for Viking Therapeutics (VKTX)

William Blair analyst Andy Hsieh maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) on September 9. The company’s shares closed last Friday at $5.73. According to TipRanks.com, Hsieh is a 4-star analyst with an average return of

Analysts Are Bullish on Top Healthcare Stocks: Pfenex (PFNX), Bristol Myers (BMY)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pfenex (PFNX – Research Report) and Bristol Myers (BMY – Research Report) with bullish sentiments. Pfenex (PFNX) In a report issued on

William Blair Keeps a Buy Rating on Seattle Genetics (SGEN)

In a report issued on June 30, Andy Hsieh from William Blair reiterated a Buy rating on Seattle Genetics (SGEN – Research Report). The company’s shares closed last Thursday at $169.53, close to its 52-week high of $175.64. According to

Exelixis (EXEL) Receives a Buy from William Blair

In a report released yesterday, Andy Hsieh from William Blair reiterated a Buy rating on Exelixis (EXEL – Research Report). The company’s shares closed last Monday at $24.14. According to TipRanks.com, Hsieh is a 5-star analyst with an average return